Shield Thera Regulatory News (STX)

 Name of applicant:

SHIELD THERAPEUTICS PLC

 

Name of scheme:

Shield Therapeutics Retention Share Plan

Period of return:

From:

31 March 2023

To:

30 September 2023

Balance of unallotted securities under scheme(s) from previous return:

39,794

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

NIL

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

NIL

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

39,794

Name of applicant:

SHIELD THERAPEUTICS PLC

 

Name of scheme:

Shield Therapeutics plc 2016 Company Share Option Plan

Period of return:

From:

31 March 2023

To:

30 September 2023

Balance of unallotted securities under scheme(s) from previous return:

341,020

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

NIL

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

NIL

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

341,020

 Name of applicant:

SHIELD THERAPEUTICS PLC

 

Name of scheme:

The Shield Therapeutics plc 2016 Long Term Incentive Plan

Period of return:

From:

31 March 2023

To:

30 September 2023

Balance of unallotted securities under scheme(s) from previous return:

24,273

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

NIL

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

NIL

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

24,273

Name of applicant:

SHIELD THERAPEUTICS PLC

Name of scheme:

Shield Therapeutics Retention and Performance Share Plan

Period of return:

From:

31 March 2023

To:

30 September 2023

Balance of unallotted securities under scheme(s) from previous return:

2,870,838

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

NIL

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

NIL

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

2,870,838

Name of contact:

Lucy Huntington-Bailey

Telephone number of contact:

+44 (0) 191 511 8500

Shield Therapeutics plc

www.shieldtherapeutics.com

Greg Madison, CEO

+44 (0) 191 511 8500

Hans-Peter Rudolf, CFO

 

 

Nominated Adviser and Joint Broker

 

Peel Hunt LLP

 

James Steel/Patrick Birkholm

+44 (0)20 7418 8900

 

Joint Broker

Cavendish Capital Markets Ltd     

Geoff Nash/ George Dollemore/Nigel Birks/Harriet Ward                                            

 

 

 

+44 (0)20 7220 0500

 

 

Financial PR & IR Advisor

 

Walbrook PR

 

Lianne Applegarth/Alice Woodings

+44 (0)20 7933 8780 or shield@walbrookpr.com

 

Investor Contact (US Advisor)

LifeSci Advisors, LLC

John Mullaly

 

 

+1 617 429 3548 or jmullaly@lifesciadvisors.com